1. Home
  2. BSM vs WGS Comparison

BSM vs WGS Comparison

Compare BSM & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Black Stone Minerals L.P.

BSM

Black Stone Minerals L.P.

HOLD

Current Price

$14.76

Market Cap

3.0B

Sector

Energy

ML Signal

HOLD

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$69.01

Market Cap

2.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSM
WGS
Founded
1876
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Retail: Computer Software & Peripheral Equipment
Sector
Energy
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.7B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
BSM
WGS
Price
$14.76
$69.01
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $93.50
AVG Volume (30 Days)
318.7K
★ 710.8K
Earning Date
11-02-2026
11-03-2026
Dividend Yield
★ 8.10%
N/A
EPS Growth
N/A
★ 62.37
EPS
★ N/A
N/A
Revenue
★ $469,919,000.00
$427,539,000.00
Revenue This Year
$13.26
$12.70
Revenue Next Year
$7.88
$24.31
P/E Ratio
$12.82
★ N/A
Revenue Growth
8.35
★ 39.97
52 Week Low
$12.74
$32.21
52 Week High
$15.49
$170.87

Technical Indicators

Market Signals
Indicator
BSM
WGS
Relative Strength Index (RSI) 53.95 36.97
Support Level $14.40 $56.36
Resistance Level $15.20 $73.21
Average True Range (ATR) 0.20 4.58
MACD 0.03 -0.82
Stochastic Oscillator 75.42 15.85

Price Performance

Historical Comparison
BSM
WGS

About BSM Black Stone Minerals L.P.

Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests. The company owns mineral interests in approximately 16.9 million gross acres.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: